Cancer Diagnostics – Products

ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies.

HeartCare Combines Testing Using Both AlloMap Gene Expression Profiling and AlloSure Donor-Derived Cell-Free DNA.

The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications.

CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility.

Yourgene Health presented data demonstrating that prolonged storage of blood in EDTA tubes is compatible with non-invasive prenatal testing (NIPT) when using size selection to enrich the fetal fraction.

Expert Intelligence (EI) announced at the 2023 ASMS conference in Houston, Texas its AI application builder for Mass Spectrometry analysis.

This digital PCR system for DNA and RNA features 6 advanced optical channels for flexible, multiplexed biomarker detection, with advances in sensitivity, precision and flexibility. The Digital LightCycler® System is a powerful digital PCR system that aims to help laboratories push the boundaries of clinical research forward

Personalis, Inc. has announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.